Nomura Holdings Inc. Acquires 133,801 Shares of Johnson & Johnson (NYSE:JNJ)

Nomura Holdings Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 114.9% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 250,245 shares of the company’s stock after buying an additional 133,801 shares during the quarter. Nomura Holdings Inc.’s holdings in Johnson & Johnson were worth $34,592,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Advisor Partners LLC grew its stake in shares of Johnson & Johnson by 11.8% during the 4th quarter. Advisor Partners LLC now owns 79,800 shares of the company’s stock valued at $10,298,000 after purchasing an additional 8,391 shares during the period. Allen Capital Group LLC grew its stake in shares of Johnson & Johnson by 11.7% during the 4th quarter. Allen Capital Group LLC now owns 19,343 shares of the company’s stock valued at $2,528,000 after purchasing an additional 2,032 shares during the period. Cambridge Advisors Inc. grew its stake in shares of Johnson & Johnson by 0.3% during the 4th quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after purchasing an additional 78 shares during the period. Atlas Capital Advisors LLC grew its stake in shares of Johnson & Johnson by 177.3% during the 4th quarter. Atlas Capital Advisors LLC now owns 16,638 shares of the company’s stock valued at $2,147,000 after purchasing an additional 10,638 shares during the period. Finally, HM Capital Management LLC grew its stake in shares of Johnson & Johnson by 11.2% during the 4th quarter. HM Capital Management LLC now owns 12,309 shares of the company’s stock valued at $1,588,000 after purchasing an additional 1,244 shares during the period. Institutional investors own 72.01% of the company’s stock.

Shares of JNJ stock traded up $1.27 during trading hours on Friday, reaching $131.38. 359,115 shares of the company traded hands, compared to its average volume of 7,392,434. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The company has a market cap of $342.22 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.19 and a beta of 0.68. The firm has a 50-day moving average price of $130.02 and a 200 day moving average price of $135.75.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the previous year, the firm earned $2.10 EPS. The business’s quarterly revenue was down 1.3% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 8.6 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $0.95 dividend. The ex-dividend date was Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.89%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

A number of equities research analysts have issued reports on the company. Raymond James cut their price target on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Barclays began coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price objective on the stock. Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Bank of America reaffirmed a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Exchange-Traded Funds (ETFs)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit